EXHIBIT 10.22
EMPLOYMENT AGREEMENT
This Employment Agreement (the "Agreement") is entered into as of April 19,
1994, by and between AASTROM BIOSCIENCES, INC., a Michigan corporation
("Employer") and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, PH.D. ("Employee").
NOW, THEREFORE, the parties agree as follows:
1. EMPLOYMENT Employer hereby engages Employee, and Employee hereby
accepts such engagement, upon the terms and conditions set forth herein.
2. DUTIES Employee is engaged as Vice President Regulatory Affairs.
Employee shall perform faithfully and diligently the duties customarily
performed by persons in the position for which employee is engaged, together
with such other reasonable and appropriate duties as Employer shall designate
from time to time. Employee shall devote Employee's full business time and
efforts to the rendition of such services and to the performance of such duties.
As a full-time employee of Employer, Employee shall not be entitled to provide
consulting services or other business or scientific services to any other party,
without the prior written consent of Employer.
3. COMPENSATION
3.1 BASE SALARY During the term of this Agreement, as compensation
for the proper and satisfactory performance of all duties to be performed by
Employee hereunder, Employer shall pay Employee at an annual salary rate of One
Hundred Ten Thousand Dollars ($110,000), payable in arrears in equal bi-weekly
installments, less required deductions for state and federal withholding tax,
Social Security and all other employee taxes and payroll deductions. The base
salary shall be subject to review and adjustment on an annual basis.
4. TERM
4.1 COMMENCEMENT The employment relationship pursuant to this
Agreement shall commence no later than May 9, 1994.
4.2 TERMINATION AT WILL Although Employer and Employee anticipate a
long and mutually rewarding employment relationship, either party may terminate
this Agreement, without cause, upon fourteen (14) days' prior written notice
delivered to the other. It is expressly understood and agreed that the
employment relationship is "at will", and with no agreement for employment for
any specified term, and with no agreement for employment for so long as Employee
performs satisfactorily. Provided, however, before Employer exercises this right
of termination at will, Employer shall first either (i) discuss with Employee
the needs of Employer and why Employee no longer meets those needs, or (ii)
discuss with Employee any concerns or dissatisfactions which
Employer has with Employee's performance, and give to Employee a reasonable
opportunity to remedy those concerns or dissatisfactions, to the reasonable
satisfaction of Employer.
4.3 TERMINATION FOR CAUSE Either party may terminate this employment
relationship immediately upon notice to the other party in the event of any good
cause, such as a default, dishonesty, neglect of duties, failure to perform by
the other party, or death or disability of Employee.
4.4 PAYMENT OF COMPENSATION UPON TERMINATION Upon termination for
cause, Employee shall be entitled to the compensation set forth as "base salary"
herein, prorated to the effective date of such termination as full compensation
for any and all claims of Employee under this Agreement.
5. FRINGE BENEFITS
5.1 CUSTOMARY FRINGE BENEFITS Employee shall be entitled to such
fringe benefits as Employer customarily makes available to employees of Employer
engaged in the same or similar position as Employee ("Fringe Benefits"). Such
Fringe Benefits may include vacation leave, sick leave, and health insurance
coverage. Employer reserves the right to change the Fringe Benefits on a
prospective basis, at any time, effective upon delivery of written notice to
Employee.
5.2 ACCUMULATION Employee shall not earn and accumulate unused
vacation in excess of fifteen (15) days. employee shall not earn and accumulate
sick leave or other fringe benefits in excess of an unused amount equal to twice
the amount earned for one year. Further, employee shall not be entitled to
receive payments in lieu of said fringe benefits, other than for unused vacation
leave earned and accumulated at the time the employment relationship terminates.
6. INVENTION, TRADE SECRETS AND CONFIDENTIALITY
6.1 DEFINITIONS
6.1.1 Invention Defined. As used herein "Invention" means
inventions, discoveries, concepts, and ideas, whether patentable or
copyrightable or not, including but not limited to processes, methods, formulas,
techniques, materials, devices, designs, programs (including computer programs),
computer graphics, apparatus, products, as well as improvements thereof or know-
how related thereto, relating to any present or anticipated business or
activities of Employer.
6.1.2 Trade Secret Defined. As used herein "Trade Secret" means,
without limitation, any document or information relating to Employer's products,
processes or services, including documents and information relating to
Inventions, and to the research, development, engineering or manufacture of
Inventions, and to Employer's purchasing, customer or supplier lists, which
documents or information have been disclosed to Employee or known to Employee as
a consequence of or through Employee's employment by Employer (including
documents, information or Inventions conceived, originated, discovered or
developed by Employee), which is not generally known in the relevant trade or
industry.
6.2 INVENTIONS
6.2.1 Disclosure. Employee shall disclose promptly to Employer
each Invention, whether or not reduced to practice, which is conceived or
learned by Employee (either alone or jointly with others) during the term of his
employment with Employer. Employee shall disclose in confidence to Employer all
patent applications filed by or on behalf of Employee during the term of his
employment and for a period of three (3) years thereafter. Any disclosure of an
Invention, or any patent application, made within one (1) year after termination
of employment shall be presumed to relate to an Invention made during Employee's
term of Employment with Employer, unless Employee clearly proves otherwise.
6.2.2 Employer Property; Assignment. Employee acknowledges and
agrees that all Inventions which are discovered, conceived, developed, made,
produced or prepared by Employee (alone or in conjunction with others) during
the duration of Employee's employment with Employer shall be the sole property
of Employer. Said property rights of Employer include without limitation all
domestic and foreign patent rights, rights of registration or other protection
under the patent and copyright laws, and all other rights pertaining to the
Inventions. Employee further agrees that all services, products and Inventions
that directly or indirectly result from engagement with Company shall be deemed
"works for hire" as that term is defined in Title 17 of the United States Codes,
and accordingly all rights associated therewith shall vest in the Company.
Notwithstanding the foregoing, Employee hereby assigns to Employer all of
Employee's right, title and interest in any such services, products and
Inventions, in the event any such services, products and Inventions shall be
determined not to constitute "works for hire."
6.2.3 Exclusion Notice. The Assignment by Employee of Inventions
under this Agreement does not apply to any Inventions which are owned or
controlled by Employee prior to the commencement of employment of Employee by
Employer (all of which are set forth on Exhibit "A" hereto). Additionally,
Employee is not required to assign an idea or invention where the invention or
idea meets all of the following criteria; namely if the invention or idea: (i)
was created or conceived without the use of any of Employer's equipment,
supplies, facilities, or trade secret information, and (ii) was developed
entirely on Employee's own time, and (iii) does not relate to the business of
Employer, and (iv) does not relate to Employer's actual or demonstrably
anticipated research or development, and (v) does not result from any work
performed by Employee for Employer.
6.2.4 Patents and Copyrights; Attorney-in Fact. Both before and
after termination of this Agreement (and with reasonable compensation paid
by Employer to Employee after termination), Employee agrees to assist the
Employer to apply for, obtain and enforce patents on, and to apply for, obtain
and enforce copyright protection and registration of, the Inventions described
in Section 6.2.2 in any and all countries. To that end, Employee shall (at
Employer's request) without limitation, testify in any proceeding, and execute
any documents and assignments determined to be necessary or convenient for use
in applying for, obtaining, registering and enforcing patent or copyright
protection involving any of the Inventions. Employee hereby irrevocably appoints
Employer, and its duly authorized officers and agents, as Employee's agent and
attorney-in-fact, to act for and in behalf of Employee in filing all patent
applications, applications for copyright protection and registration,
amendments, renewals, and all other appropriate documents in any way related to
the Inventions described in Section 6.2.2.
6.3 TRADE SECRETS
6.3.1 Acknowledgment of Proprietary Interest. Employee recognizes
the proprietary interest of Employer in any Trade Secrets of Employer. Employee
acknowledges and agrees that any and all Trade Secrets of Employer, whether
developed by Employee alone or in conjunction with others or otherwise, shall be
and are the property of Employer.
6.3.2 Covenant Not to Divulge Trade Secrets. Employee acknowledges
and agrees that Employer is entitled to prevent the disclosure of Trade Secrets
of Employer. As a portion of the consideration for the employment of Employee
and for the compensation being paid to Employee by Employer, Employee agrees at
all times during the term of the employment by Employer and thereafter to hold
in strictest confidence, and not to use, disclose or allow to be disclosed to
any person, firm, or corporation, Trade Secrets of Employer, including Trade
Secrets developed by Employee, other than disclosures to persons engaged by
Employer to further the business of Employer, and other than use in the pursuit
of the business of Employer.
6.3.3 Confidential Information of Others. Employee represents and
warrants that if Employee has any confidential information belonging to others,
Employee will not use or disclose to Employer any such information or documents.
Employee represents that his employment with Employer will not require him to
violate any obligation to or confidence with any other party.
6.4 NO ADVERSE USE Employee will not at any time use Employer's Trade
Secrets or Inventions in any manner which may directly or indirectly have an
adverse effect upon Employer's business, nor will Employee perform any acts
which would tend to reduce Employer's proprietary value in Employer's Trade
Secrets or Inventions.
6.5 RETURN OF MATERIALS AT TERMINATION In the event of any
termination of Employee's employment, Employee will promptly deliver to Employer
all materials, property, documents, data, and other information
belonging to Employer or pertaining to Trade Secrets or Inventions. Employee
shall not take any materials, property, documents or other information, or any
reproduction or excerpt thereof, belonging to Employer or containing or
pertaining to any Trade Secrets or Inventions.
6.6 REMEDIES UPON BREACH In the event of any breach by Employee of
the provision in this Section 6, Employer shall be entitled, if it so elects, to
institute and prosecute proceedings in any court of competent jurisdiction,
either in law or in equity, to enjoin Employee from violating any of the terms
of this Section 6, to enforce the specific performance by Employee of any of the
terms of this Section 6, and to obtain damages for any of them, but nothing
herein contained shall be construed to prevent such remedy or combination of
remedies as Employer may elect to invoke. The failure of Employer to promptly
institute legal action upon any breach of this Section 6 shall not constitute a
waiver of that or any other breach hereof.
7. COVENANT NOT TO COMPETE Employee agrees that, during Employee's
employment, Employee will not directly or indirectly compete with Employer in
any way, and that Employee will not act as an officer, director, employee,
consultant, shareholder, lender or agent of any other entity which is engaged in
any business of the same nature as, or in competition with, the business in
which Employer is now engaged, or in which Employer becomes engaged during the
term of Employee's employment, or which is involved in science or technology
which is similar to Employer's science or technology.
8. GENERAL PROVISIONS
8.1 ATTORNEYS' FEES In the event of any dispute or breach arising
with respect to this Agreement, the party prevailing in any negotiations or
proceedings for the resolution or enforcement thereof shall be entitled to
recover from the losing party reasonable expenses, attorneys' fees and costs
incurred therein.
8.2 AMENDMENTS No amendment or modification of the terms or
conditions of this Agreement shall be valid unless in writing and signed by both
parties hereto. There shall be no implied-in-fact contracts modifying the terms
of this Agreement.
8.3 ENTIRE AGREEMENT This Agreement constitutes the entire agreement
between the parties with respect to the employment of Employee. This Agreement
supersedes all prior agreements, understandings, negotiations and representation
with respect to the employment relationship.
8.4 SUCCESSORS AND ASSIGNS The Rights and obligations of Employer
under this Agreement shall inure to the benefit of and shall be binding upon the
successors and assigns of Employer. Employee shall not be entitled to assign any
of Employee's rights or obligations under this Agreement.
8.5 WAIVER Either party's failure to enforce any provision of this
Agreement shall not in any way be construed as a waiver of any such provision,
or prevent that party thereafter from enforcing each and every other provision
of this Agreement.
8.6 SEVERABLE PROVISIONS The provisions of this Agreement are
severable, and if any or more provisions may be determined to be judicially
unenforceable, in whole or in part, the remaining provisions shall nevertheless
be binding and enforceable.
9. EMPLOYEE'S REPRESENTATIONS Employee represents and warrants that
Employee (i) is free to enter into this Agreement and to perform each of the
terms and covenants contained herein, (ii) is not restricted or prohibited,
contractually or otherwise, from entering into and performing this Agreement,
and (iii) will not be in violation or breach of any other agreement by reason of
Employee's execution and performance of this Agreement.
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
set forth above.
EMPLOYER:
Aastrom Biosciences, Inc.
By: /s/ R. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
---------------------------
R. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, Ph.D.
President and CEO
EMPLOYEE:
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Ph.D.
Address: ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Exhibit A
List of Prior Inventions
(Section 6.2.3)
None, other than the following:
See attached list of patents and publications.
------------------------------------------------------------------------------
------------------------------------------------------------------------------
------------------------------------------------------------------------------
------------------------------------------------------------------------------
------------------------------------------------------------------------------
------------------------------------------------------------------------------
------------------------------------------------------------------------------
------------------------------------------------------------------------------
1- ▇.▇. ▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Xanthation", Technical Report No. 192, Pulp
and Paper Research Institute of Canada (July, 1960).
2- ▇.▇. ▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Xanthation and Dexanthation of Cellulose and
Related Glucose Derivatives", Canadian Textile Journal 42 (March, 1963).
3- ▇.▇. ▇▇▇▇▇▇ and ▇. ▇. ▇▇▇▇▇▇ "Xanthation", Chapter 43 in "Methods in
Carbohydrate Chemistry", Vol. III, Academic Press, Inc., NY (1963).
4- ▇.▇. ▇▇▇▇▇▇ and ▇. ▇. ▇▇▇▇▇▇▇▇▇ "Fractional Turbidimetric Analysis of the
Molar Substitution of Hydroxyethyl Cellulose", Journal of Applied Polymer
Science 10, 1285 (1966).
--
5- ▇.▇. ▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Effect of Orientation and Trace Crosslinking on
the Properties of High Wet Modulus Rayon", Journal of Applied Polymer
Science 12, 487 (1968).
--
6- ▇.▇. ▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇▇▇▇ "Characterization of the Chain Length
Distribution of Wood Celluloses by Gel Permeation Chromatography", Journal
of Polymer Science Part C, 21, 283 (1968).
--
7- D. Tunc, ▇.▇. ▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Quantitative Determination of
Xanthate, Byproduct and Total Sulfur in Viscose by Ultraviolet
Spectrophotometry", TAPPI 52, 1882 (1969).
--
8- ▇.▇. ▇▇▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Applications of Gel Chromatography in the
Pulping Process", Journal of Polymer Science Part C, 36, 87 (1971).
--
9- ▇.▇. ▇▇▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Evaluation of Pulps, Rayon Fibers and
Cellulose Acetate by GPC and Other Fractionation Methods", Separation
Sciences 6, (1), 47 (FEB., 1971).
-
10- ▇.▇. ▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, H.D. ▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇ "Process and
Forming Hydroxyl Cellulose Fibers Having Water Absorption and High Water
Retention Properties", U.S. Patent 3,670,069 (June 13, 1972); British
Patent 1,324,373 (July 25, 1973).
▇▇- ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇ and S.E. Church "Chemical Cellulose for High
Performance Rayon", TAPPI 1973 Dissolving Pulps Conference Preprints
(Oct., 1973).
12- H.D. ▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Process for Producing High Performance
Crimped Rayon Staple Fiber", U.S. Patent 3,720,743 (March 13, 1973);
German Patent 1,342,805 (Jan. 3, 1974); Canadian Patent 960,422 (Jan. 7,
1975).
13- ▇.▇. ▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, H.D. ▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇ "Wet Spinning of
Cellulosic Products", U.S. Patent 3,865,918 (Feb. 11, 1975).
14- ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇ and L.L. Nejelski "The New Rayons", 33rd Annual
Technical Conference Society Plastics Engineers, Atlanta, GA (May 5-8,
1975).
15- ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇ and ▇.▇. ▇▇▇▇ "High Performance Crimped Rayon
Fiber", Textile Research Journal 46, 184 (1976).
--
16- ▇.▇. ▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "World Textile Fiber Demand Projected to 2000
A.D.; Technology for the Production of a Chemically Crimped HWM Rayon
Fiber", SASMIRA Conference, New Delhi, India (Jan. 19-21, 1976);
"Proceedings of the International Conference on Man-Made Fibres for
Developing Countries" (1976).
17- ▇.▇. ▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇ "Process Technology and Applications for a
Chemically Crimped HWM Rayon Fiber", Eighth ▇▇▇▇▇▇▇ International Seminar,
Manchester, England (April 27-29, 1976).
18- ▇.▇. ▇▇▇▇▇▇ "Man-Made Cellulosic Fibers - A View in 1976", Comite
International de la Rayonne et des Fibres Synthetiques, Paris, France
(Oct. 14, 1976).
19- ▇.▇. ▇▇▇▇▇▇ "Review of Modern Viscose Processing and Recovery Techniques"
Seminars Presented at the U.S. Embassy, Moscow (Jan. 10-12, 1978).
20- ▇.▇. ▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇ "Modified Cellulosics - An Overview of the
Future", Modified Cellulosics, Academic Press, Inc., NY (1978).
21- ▇.▇. ▇▇▇▇▇▇ "Research, Development and Production of Silvichemicals",
Natl. Meeting Am. Inst. Chem. Eng., Philadelphia, PA (June 7, 1978).
22- ▇.▇. ▇▇▇▇▇▇ "Energy and Chemical Requirements for the Manufacture of
Chemical Cellulose from Wood, HWM Rayon Staple Fiber and Polyester Staple
Fiber", Comite International de la Rayonne et des Fibres Synthetiques,
Paris, France (Oct. 1978).
23- ▇.▇. ▇▇▇▇▇▇ "Cellulosics", Seminars Presented for Chinese Industry,
Shanghai, China (May 20-21, 1979).
24- ▇.▇. ▇▇▇▇▇▇ "High Wet Modulus Rayon Fiber (Prima)", Industrial Research
IR-100 Award (Oct., 1979).
25- ▇.▇. ▇▇▇▇▇▇ "New Cellulose Fibers and Processes", Eighteenth International
Man-Made Fibre Conference, Dornbirn, Austria (June 20, 1979); Lenzinger
Berichte 48, 87 (March, 1980).
--
26- ▇.▇. ▇▇▇▇▇▇ "Developments in the Manufacture of Regenerated Cellulose
Fibers and Films", Chairman, TAPPI Dissolving Pulps Conference, Vienna,
Austria (Oct. 9, 1980).
27- H.O. ▇▇▇▇▇▇▇▇, C. J-P. Mullon, ▇.▇. ▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇▇▇ "Hollow Fiber
Liver Support System", Am. Inst. Chem. Eng. Annual Meeting, San Francisco,
CA (Nov. 5-10, 1989).
28- ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, A.P.
Monaco and ▇.▇. Chick "The Hybrid Perfused Pancreas: Successful Treatment
of Severely Diabetic Pancreatectomized Dogs", Tenth Workshop of the
European Association for the Study of Diabetes, Amsterdam, The Netherlands
(Jan. 27-29, 1991).
29- ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ "Maintenance of Normoglycemia in Diabetic Dogs with an
Artificial Pancreas", Presented at Swiss Federal Institute of Technology
(ETH), Zurich, Switzerland (Jan. 31, 1991).
30- ▇. ▇▇▇▇, ▇.▇. ▇▇▇▇, ▇. ▇▇▇▇▇▇▇-▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. Chick and A.P. Monaco "The Biohybrid Artificial
Pancreas for Treatment of Diabetes in Totally Pancreatectomized Dogs",
XIII Int. Congress of the Transplantation Society (August ▇▇-▇▇, ▇▇▇▇) ▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇; Transplantation Proceedings 23 (1), 754-755 (1991).
--
31- ▇.▇. Chick, ▇.▇. ▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇ and ▇.▇. ▇▇▇▇▇ "Artificial
Pancreatic Perfusion Device", U.S. Patent 5,002,661 (March 26, 1991).
32- ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇,
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, and ▇▇▇▇▇▇▇ ▇.
Chick "Biohybrid Artificial Pancreas: Long-Term Implantation Studies in
Diabetic, Pancreatectomized Dogs", Science 252, 718 (1991).
---
33- H. Ohzato, ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇,
▇.▇. ▇▇▇▇▇▇▇, ▇.▇. Chick and A.P. Monaco "Use of Xenogeneic Islets in
Hybrid Artificial Pancreas for Treatment of Diabetes Without Immuno-
suppression", First International Congress of Xenotransplantation,
Minneapolis Transplant Congress, Minneapolis, MN, August 25-28, 1991;
Transplantation Proceedings 24 (2) 661-662 (1992).
--
▇▇- ▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇.
▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇.
Chick and ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ "Islet Xenotransplantation Without Immuno-
suppression Utilizing the Hybrid Artificial Pancreas", Third International
Symposium on Islet Transplantation, Perugia, Italy, (Sept. 26-29, 1991);
Diab. Nutr. Metab. (in Press).
35- ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇,
▇▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇ ▇. Chick
"Transplantation of Islet Allografts and Xenografts in Totally
Pancreatectomized Diabetic Dogs Using the Hybrid Artificial Pancreas",
Annals of Surgery, 214 (3), 339-362 (1991).
---
▇▇- ▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇▇▇, ▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇. Chick and ▇▇▇▇▇▇▇
▇. ▇▇▇▇▇▇ "Successful Treatment of Diabetes with the Biohybrid Artificial
Pancreas in Dogs", 16th Annual Meeting American Society of Transplant
Surgeons, Chicago, IL (May 30-June 1, 1990); Transplantation 51, 43-51,
--
(1991).
37- ▇.▇. ▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇, ▇. ▇▇▇▇, A.P. Monaco and
▇.▇. Chick "Xenotransplantation of Canine, Bovine, and Porcine Islets in
Diabetic Rats Without Immunosuppression", Proc. Natl. Acad. Sci. USA,
Acad. Sci. USA, 88--11100-11104 (1991).
--
38- ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, A.P. Monaco, T. ▇▇▇▇, ▇.▇. Chick, and ▇.▇.
▇▇▇▇▇▇▇▇ "Maintenance of Normoglycemia in Diabetic Dogs with an Artificial
Pancreas", Study Group of the European Association for the Study of
Diabetes, Igls, Austria (Jan. 26-28, 1992).
39- ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ "Long-Term Cultures of Adult
Mammalian Hepatocytes in Hollow Fibers as the Cellular Component of
Extracorporeal (Hybrid) Liver Assist Devices", Artif. Organs 16 (2), 209-
--
212 (1992).
▇▇- ▇.▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇, M.D. ▇▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, A.P. Monaco and ▇.▇. Chick "Implantation of the
Biohybrid Pancreas in Diabetic Dogs", Third International Congress on
Pancreatic and Islet Transplantation Symposium on Artificial Insulin
Delivery System, Lyon, France, (June 6-8, 1991); Transplantation
Proceedings 24 (3), 942-944 (1992).
▇▇- ▇.▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇, M.D. ▇▇▇▇▇▇▇,
▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, A.P. Monaco and ▇.▇. Chick "Evaluation of the
Hybrid Artificial Pancreas in Diabetic Dogs", ASAIO Journal Transactions
on Hybrid Organs and Cell Therapy 38 (1), 29 (1992).
--
42- ▇.▇. ▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇, ▇. ▇▇▇▇, A.P. Monaco and ▇.▇. Chick
"Successful Xenotransplantation of a Diffusion-Based Biohybrid Artificial
Pancreas: A Study Using Canine, Bovine, and Porcine Islets", First
International Congress on Xenotransplantation, Minneapolis Transplant
Congress, Minneapolis, MN, (August 25-28, 1991); Transplantation
Proceedings 24, 669-671 (1992).
--
43- ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ "Combination Medical Products", Presented at the Joint
FDA-HIMA Conference, Washington, DC (February 11-12, 1992).
44- ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇, P.
Lodge, ▇. ▇▇▇▇▇▇, A. Monaco, ▇. ▇▇▇▇▇▇▇ and W. Chick "Pancreatic Islet
Transplantation Using an Immunoprotective Membrane", 38th Annual Meeting
of the ASAIO Nashville, TN (May 7-9, 1992).
45- ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇
▇▇▇▇, ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ and ▇▇▇▇▇▇▇ ▇. Chick "Pancreatic Islet
Transplantation Using Membrane Diffusion ▇▇▇▇▇▇▇▇", First Int. Congress
Cell Transplant Society, Pittsburgh, PA (May 31-June 3, 1992);
Transplantation Proceedings ▇▇ (▇) ▇▇▇▇-▇▇▇▇ (1992).
--
▇▇- ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇, P. Lodge, ▇.
▇▇▇▇▇▇, A. Monaco, ▇. ▇▇▇▇▇▇▇ and W. Chick, "Islet Transplantation Using
an Immuno-protective Vascular Device", First Int. Congress Cell Transplant
Society, Pittsburgh, PA, (May 31-June 3, 1992).
47- H.O. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇, ▇. ▇▇▇▇, ▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇ and
▇. ▇▇▇▇▇▇▇ "Use of Artificial (Hybrid) Liver Support System to Treat the
Galactosamine Rabbit Model of Hepatic Encephalopathy", International
Association for the Study of the Liver Biennial Scientific Meeting,
Brighton, England (June 3-6, 1992).
48- ▇.▇. ▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇▇, P. Lodge, ▇. ▇▇▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇, A.P. Monaco and ▇.▇. Chick, "Treatment of
Severely Diabetic, Pancreatectomized Dogs Using a Diffusion-based Hybrid
Artificial Pancreas", 16th Annual Meeting of American Diabetes
Association, San Antonio, TX, (June 20-23, 1992); Diabetes 41, 886-89
(1992).
49- ▇.▇. ▇▇▇▇▇, P. Lodge, ▇.▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇▇, A.M.
▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇. ▇▇▇▇, A.P. Monaco and ▇.▇. Chick
"Transplantation of Islet Allografts Using a Diffusion-Based Biohybrid
Artificial Pancreas: Long-Term Studies in Diabetic, Pancreatectomized
Dogs", XIVth International Congress of the Transplantation Society, Paris,
France (August 16-21, 1992); Transplantation Proceedings 25 (1), 978-980
(1993). --
50- ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ "New Combination Therapies", Inst. International Res.
Seminar, Washington, DC, January 25-27 (1993).
51- ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ "Medical Therapies Based on Advanced Biomedical
Engineering Technologies", Visiting Professor Lecture, INFA (International
Faculty of Artificial Organs) Symposium, Univ. Gent. Belgium (Oct. 1,
1993).
▇▇- ▇.▇. ▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇▇, ▇.▇.
▇▇▇▇▇▇▇, ▇. ▇▇▇▇, A.P. Monaco and ▇.▇. Chick "Transplantation of Canine
Islets Into Spontaneously Diabetic BB/Wor Rats Without Immuno-
suppression", Endocrinology (in Press).
53- ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇
▇. ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇. Press, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ and ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
"Hollow Fiber Liver Assist Device for Extracorporeal Treatment of
Experimental Fulminant Hepatic Failure", Proceedings of the National
Academy of Sciences (Submitted).